AU2014292236B2 - New azabenzimidazole derivatives - Google Patents
New azabenzimidazole derivatives Download PDFInfo
- Publication number
- AU2014292236B2 AU2014292236B2 AU2014292236A AU2014292236A AU2014292236B2 AU 2014292236 B2 AU2014292236 B2 AU 2014292236B2 AU 2014292236 A AU2014292236 A AU 2014292236A AU 2014292236 A AU2014292236 A AU 2014292236A AU 2014292236 B2 AU2014292236 B2 AU 2014292236B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- chloro
- group
- pyridin
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- LSRDTCMNGSMEEI-UHFFFAOYSA-N BrCc1nc(Br)ccc1 Chemical compound BrCc1nc(Br)ccc1 LSRDTCMNGSMEEI-UHFFFAOYSA-N 0.000 description 1
- IELORWUAPRVYLB-UHFFFAOYSA-N C1NCC2C1CSC2 Chemical compound C1NCC2C1CSC2 IELORWUAPRVYLB-UHFFFAOYSA-N 0.000 description 1
- WGAQOPLIGHIXGP-XKGGJISMSA-N CC(C)(C)[Si+](C)(C)/[O]=C(\CO[C@@H]12)/[C@H]1OC[C@H]2Oc1nc2cc(Cl)c(-c3ccc([C@H](CC4)CC[C@H]4SC(C)=O)cc3)nc2[n]1COCC[Si+](C)(C)C Chemical compound CC(C)(C)[Si+](C)(C)/[O]=C(\CO[C@@H]12)/[C@H]1OC[C@H]2Oc1nc2cc(Cl)c(-c3ccc([C@H](CC4)CC[C@H]4SC(C)=O)cc3)nc2[n]1COCC[Si+](C)(C)C WGAQOPLIGHIXGP-XKGGJISMSA-N 0.000 description 1
- KOGVUOYANRITDB-FAFWTLICSA-N CC(C)(C)[Si+](C)(C)O[C@H](CO[C@@H]12)[C@H]1OC[C@H]2Oc1nc2cc(Cl)c(-c3ccc(C(CC4)CCC4SC)cc3)nc2[n]1COCC[Si+](C)(C)C Chemical compound CC(C)(C)[Si+](C)(C)O[C@H](CO[C@@H]12)[C@H]1OC[C@H]2Oc1nc2cc(Cl)c(-c3ccc(C(CC4)CCC4SC)cc3)nc2[n]1COCC[Si+](C)(C)C KOGVUOYANRITDB-FAFWTLICSA-N 0.000 description 1
- CUWLZTWATSSMRW-CWAJCYHTSA-N CC(C)(C)[Si+](C)(C)O[C@H](CO[C@@H]12)[C@H]1OC[C@H]2Oc1nc2cc(Cl)c(-c3ccc([C@H](CC4)CC[C@H]4S(C)(=NC(C(F)(F)F)=O)=O)cc3)nc2[n]1COCC[Si+](C)(C)C Chemical compound CC(C)(C)[Si+](C)(C)O[C@H](CO[C@@H]12)[C@H]1OC[C@H]2Oc1nc2cc(Cl)c(-c3ccc([C@H](CC4)CC[C@H]4S(C)(=NC(C(F)(F)F)=O)=O)cc3)nc2[n]1COCC[Si+](C)(C)C CUWLZTWATSSMRW-CWAJCYHTSA-N 0.000 description 1
- GAHMOFCUPXRSAF-UHFFFAOYSA-N CC(CCOC[n]1c(OC(COC23)C2OCC3O)nc2cc(Cl)c(-c(cc3)ccc3-c(nc3)ccc3NSC)nc12)S(C)C Chemical compound CC(CCOC[n]1c(OC(COC23)C2OCC3O)nc2cc(Cl)c(-c(cc3)ccc3-c(nc3)ccc3NSC)nc12)S(C)C GAHMOFCUPXRSAF-UHFFFAOYSA-N 0.000 description 1
- MMTHYMSLYFCVEY-BOYCAYBYSA-N CC(CO[C@@H]12)[C@H]1OC[C@H]2Oc1nc2cc(Cl)c(-c3ccc(B4OC(C)(C)C(C)(C)O4)cc3)nc2[n]1COCC[Si+](C)(C)C Chemical compound CC(CO[C@@H]12)[C@H]1OC[C@H]2Oc1nc2cc(Cl)c(-c3ccc(B4OC(C)(C)C(C)(C)O4)cc3)nc2[n]1COCC[Si+](C)(C)C MMTHYMSLYFCVEY-BOYCAYBYSA-N 0.000 description 1
- UCJWKHMENCBFMW-VPBSJLSFSA-N CCCOC[n]1c(O[C@H](CO[C@@H]23)[C@H]2OCC3O)nc2cc(Cl)c(-c(cc3)ccc3N=S(C)(c3ccncc3)=O)nc12 Chemical compound CCCOC[n]1c(O[C@H](CO[C@@H]23)[C@H]2OCC3O)nc2cc(Cl)c(-c(cc3)ccc3N=S(C)(c3ccncc3)=O)nc12 UCJWKHMENCBFMW-VPBSJLSFSA-N 0.000 description 1
- GVAMUSQAHIWACM-UHFFFAOYSA-N CS(C)(=NCc1nc(Br)ccc1)=O Chemical compound CS(C)(=NCc1nc(Br)ccc1)=O GVAMUSQAHIWACM-UHFFFAOYSA-N 0.000 description 1
- IYIIAWRCCCSATH-DZFGPLHGSA-N C[C@@H](CO[C@@H](COC1)[C@@H]1Oc([n](COCC[Si+](C)(C)C)c1n2)nc1cc(Cl)c2I)O[Si+](C)(C)C(C)(C)C Chemical compound C[C@@H](CO[C@@H](COC1)[C@@H]1Oc([n](COCC[Si+](C)(C)C)c1n2)nc1cc(Cl)c2I)O[Si+](C)(C)C(C)(C)C IYIIAWRCCCSATH-DZFGPLHGSA-N 0.000 description 1
- OJNTYTLYYKZAQK-NKCATTGYSA-N C[C@H](CO[C@@H]12)[C@H]1OC[C@H]2Oc1nc2cc(Cl)c(-c(cc3)ccc3-c3cccc(N=S(C)(C)=O)n3)nc2[nH]1 Chemical compound C[C@H](CO[C@@H]12)[C@H]1OC[C@H]2Oc1nc2cc(Cl)c(-c(cc3)ccc3-c3cccc(N=S(C)(C)=O)n3)nc2[nH]1 OJNTYTLYYKZAQK-NKCATTGYSA-N 0.000 description 1
- BZEKNFPTZLSJJF-GWMCEBHCSA-N C[C@H](CO[C@@H]12)[C@H]1OC[C@H]2Oc1nc2cc(Cl)c(-c3ccc(-c(cc4)ccc4N=S(C)C)nc3)nc2[nH]1 Chemical compound C[C@H](CO[C@@H]12)[C@H]1OC[C@H]2Oc1nc2cc(Cl)c(-c3ccc(-c(cc4)ccc4N=S(C)C)nc3)nc2[nH]1 BZEKNFPTZLSJJF-GWMCEBHCSA-N 0.000 description 1
- WHBOCRAARHXOCF-BAWFOZSCSA-N C[Si+](C)(C)CCOC[n]1c(OC(CO[C@@H]23)[C@H]2OC[C@H]3O)nc2cc(Cl)c(-c(cc3)ccc3C(O)=O)nc12 Chemical compound C[Si+](C)(C)CCOC[n]1c(OC(CO[C@@H]23)[C@H]2OC[C@H]3O)nc2cc(Cl)c(-c(cc3)ccc3C(O)=O)nc12 WHBOCRAARHXOCF-BAWFOZSCSA-N 0.000 description 1
- NOUFUXMXOIYYTL-PMVMPFDFSA-N C[Si+](C)(C)CCOC[n]1c(O[C@@H]2COCC2)nc2cc(Cl)c(-c3ccc([C@H](CC4)CC[C@@H]4O)cc3)nc12 Chemical compound C[Si+](C)(C)CCOC[n]1c(O[C@@H]2COCC2)nc2cc(Cl)c(-c3ccc([C@H](CC4)CC[C@@H]4O)cc3)nc12 NOUFUXMXOIYYTL-PMVMPFDFSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13176929.1 | 2013-07-17 | ||
| EP13176929 | 2013-07-17 | ||
| PCT/EP2014/065004 WO2015007669A1 (en) | 2013-07-17 | 2014-07-14 | New azabenzimidazole derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014292236A1 AU2014292236A1 (en) | 2016-01-21 |
| AU2014292236B2 true AU2014292236B2 (en) | 2018-11-08 |
Family
ID=48790302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014292236A Ceased AU2014292236B2 (en) | 2013-07-17 | 2014-07-14 | New azabenzimidazole derivatives |
Country Status (20)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3180338B1 (en) * | 2014-08-11 | 2018-05-09 | Boehringer Ingelheim International GmbH | Azabenzimidazole derivatives as amp protein kinase agonistes |
| CN107108605A (zh) | 2014-08-27 | 2017-08-29 | 盐野义制药株式会社 | 具有ampk活化作用的氮杂吲哚衍生物 |
| CN107108521A (zh) | 2014-10-28 | 2017-08-29 | 盐野义制药株式会社 | 具有ampk活化作用的杂环衍生物 |
| US10053471B2 (en) * | 2015-01-16 | 2018-08-21 | Boehringer Ingelheim International Gmbh | Azabenzimidazole derivatives |
| WO2017146186A1 (ja) | 2016-02-26 | 2017-08-31 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有する５－フェニルアザインドール誘導体 |
| EP3459949A4 (en) * | 2016-05-20 | 2020-04-08 | Shionogi & Co., Ltd | 5-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE AND 5-SUBSTITUTED AZABENZIMIDAZOLE DERIVATIVE WITH AMPK ACTIVATION EFFECT |
| JP2022508751A (ja) * | 2018-10-15 | 2022-01-19 | ゲロ ディスカバリー リミテッド ライアビリティ カンパニー | Ｐｆｋｆｂ３阻害剤とその使用 |
| UY38941A (es) | 2019-11-11 | 2021-06-30 | Pi Industries Ltd | Nuevas sulfiliminas o sulfoximinas que contienen compuestos heterocíclicos fungicidas |
| MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| WO2022052958A1 (en) | 2020-09-10 | 2022-03-17 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| KR20250168210A (ko) | 2023-02-16 | 2025-12-02 | 가셔브룸 바이오, 인크. | 헤테로시클릭 glp-1 효능제 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008008895A1 (en) * | 2006-07-13 | 2008-01-17 | Smithkline Beecham Corporation | Gpr119 agonists for the treatment of diabetes and related disorders |
| WO2012116145A1 (en) * | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101889993B1 (ko) | 2010-09-10 | 2018-08-20 | 시오노기세야쿠 가부시키가이샤 | Ａｍｐｋ 활성화 작용을 갖는 헤테로환 축합 이미다졸 유도체 |
| ES2755087T3 (es) * | 2012-08-22 | 2020-04-21 | Merck Sharp & Dohme | Derivados de benzimidazol hexahidrofuro[3,2-b]furano útiles como activadores de proteína cinasa activada por AMP |
| EP2888005B1 (en) * | 2012-08-22 | 2019-04-03 | Merck Sharp & Dohme Corp. | Novel azabenzimidazole hexahydrofuro[3,2-b]furan derivatives |
| WO2014069426A1 (ja) * | 2012-10-31 | 2014-05-08 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有するベンズイミダゾールおよびアザベンズイミダゾール誘導体 |
-
2014
- 2014-07-14 CN CN201480040799.5A patent/CN105377857B/zh active Active
- 2014-07-14 HU HUE14738531A patent/HUE038261T2/hu unknown
- 2014-07-14 KR KR1020167004147A patent/KR20160033749A/ko not_active Withdrawn
- 2014-07-14 AU AU2014292236A patent/AU2014292236B2/en not_active Ceased
- 2014-07-14 EP EP14738531.4A patent/EP3022210B1/en active Active
- 2014-07-14 MX MX2016000547A patent/MX359040B/es active IP Right Grant
- 2014-07-14 DK DK14738531.4T patent/DK3022210T3/en active
- 2014-07-14 CA CA2918401A patent/CA2918401A1/en not_active Abandoned
- 2014-07-14 PL PL14738531T patent/PL3022210T3/pl unknown
- 2014-07-14 TR TR2018/06860T patent/TR201806860T4/tr unknown
- 2014-07-14 ES ES14738531.4T patent/ES2669543T3/es active Active
- 2014-07-14 JP JP2016526557A patent/JP6491656B2/ja active Active
- 2014-07-14 EA EA201600113A patent/EA032195B1/ru not_active IP Right Cessation
- 2014-07-14 WO PCT/EP2014/065004 patent/WO2015007669A1/en not_active Ceased
- 2014-07-15 US US14/331,359 patent/US9492436B2/en active Active
- 2014-07-16 AR ARP140102623A patent/AR096936A1/es unknown
- 2014-07-16 TW TW103124425A patent/TW201546076A/zh unknown
- 2014-07-17 UY UY0001035668A patent/UY35668A/es unknown
-
2016
- 2016-01-07 CL CL2016000026A patent/CL2016000026A1/es unknown
- 2016-01-14 PH PH12016500092A patent/PH12016500092B1/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008008895A1 (en) * | 2006-07-13 | 2008-01-17 | Smithkline Beecham Corporation | Gpr119 agonists for the treatment of diabetes and related disorders |
| WO2012116145A1 (en) * | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
Also Published As
| Publication number | Publication date |
|---|---|
| AR096936A1 (es) | 2016-02-10 |
| CA2918401A1 (en) | 2015-01-22 |
| TW201546076A (zh) | 2015-12-16 |
| TR201806860T4 (tr) | 2018-06-21 |
| AU2014292236A1 (en) | 2016-01-21 |
| MX359040B (es) | 2018-09-13 |
| CN105377857B (zh) | 2018-04-10 |
| UY35668A (es) | 2015-01-30 |
| CL2016000026A1 (es) | 2016-08-12 |
| HUE038261T2 (hu) | 2018-10-29 |
| US9492436B2 (en) | 2016-11-15 |
| EA201600113A1 (ru) | 2016-07-29 |
| MX2016000547A (es) | 2016-04-20 |
| KR20160033749A (ko) | 2016-03-28 |
| JP2016527223A (ja) | 2016-09-08 |
| DK3022210T3 (en) | 2018-06-06 |
| US20150025065A1 (en) | 2015-01-22 |
| PH12016500092B1 (en) | 2019-04-12 |
| PL3022210T3 (pl) | 2018-08-31 |
| CN105377857A (zh) | 2016-03-02 |
| ES2669543T3 (es) | 2018-05-28 |
| EA032195B1 (ru) | 2019-04-30 |
| EP3022210A1 (en) | 2016-05-25 |
| PH12016500092A1 (en) | 2016-04-18 |
| WO2015007669A1 (en) | 2015-01-22 |
| JP6491656B2 (ja) | 2019-03-27 |
| EP3022210B1 (en) | 2018-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3022210B1 (en) | New azabenzimidazole derivatives | |
| EP3180338B1 (en) | Azabenzimidazole derivatives as amp protein kinase agonistes | |
| EP3532458A1 (en) | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | |
| US10053471B2 (en) | Azabenzimidazole derivatives | |
| EP3245210B1 (en) | New azabenzimidazole derivatives as agonists of the amp-activated protein kinase | |
| JP6474804B2 (ja) | アザベンゾイミダゾール誘導体 | |
| EP2847196B1 (en) | New 2,3-dihydro-furo[2,3-c]pyridines, their use as modulators of the g-protein-coupled receptor gpr119 and pharmaceutical compositions comprising them | |
| EP2820022B1 (en) | Furo[2,3-c]pyridines actives on gpr 119 | |
| WO2014037327A1 (en) | N-cyclopropyl-n-piperidinyl-amides, pharmaceutical compositions containing them, and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |